Joseph Haas is a Senior Writer at Informa. He specializes in medicine and healthcare, with a focus on medical technology, alternative medicine, and various medical specialties, as well as business and economics within the healthcare sector. His work has been featured in notable publications including Informa, Citeline, and MDEdge.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Joseph Haas focuses on the healthcare and pharmaceutical industry, particularly mergers and acquisitions, drug development, and clinical trials. His coverage heavily features press releases from pharmaceutical companies and private sector announcements.
Given this focus, Joseph would likely be interested in pitches related to new M&A deals in the biopharmaceutical industry or significant advancements in drug development. Sources with insights into the strategic aspects of these transactions or specific clinical trial results may capture his attention.
When reaching out to Joseph, it's important to have access to reliable data that supports any claims being made as he frequently cites data in his articles. Additionally, understanding the intricacies of the biopharmaceutical industry will be crucial when crafting a pitch for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Lilly's business development chief Jake Van Naarden reviews the firm's 31 deals so far in 2026 and the strategies and priorities underlying that activity.
With PAH drug Winrevair up 75% year-over-year and COPD drug Ohtuvayre off to a solid launch, the cardiometabolic/respiratory disease franchise drove second-quarter growth for Merck.
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
By: Lisa Takagi, Joseph Haas, Dexter Jie Yan
Plus deals involving Alphamab/Pathos AI, Taisho/Kaigene, LTT Bio-Pharma/Apogepha, Sino Biopharmaceutical/PT Tempo, Nippon Shinyaku/Aquelys, Qilu/TYK and more.
By: Joseph Haas, Alaric DeArment
Sarepta's revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.
Plus deals involving Arcturus/CSL, Harrow/Viatris, Evotec/Odyssey, Processa/Vidya, Scancell/Neuphoria as well as the latest technology transfer agreements.
By: Joseph Haas, Dexter Jie Yan, Lisa Takagi
Plus deals involving Fulcrum/Slate, Oblenio/Leads Biolabs, GSK/Chugai, IASO/MediSix, Innate/SOBI and more.
Bausch + Lomb said its eye drop combining the active ingredients from Xiidra and Miebo will soon move into Phase III. The firm is also bullish on a Phase II ocular surface pain candidate.
By: Joseph Haas
Deal snapshot: South Korea's SK Biopharmaceuticals will add opakalim to its epilepsy portfolio, paying Biohaven $350m at closing for the Phase II/III ion channel modulator.
By: Joseph Haas
Roivant's Priovant subsidiary gained US approval of brepocitinib in dermatomyositis. Priovant is pursuing additional indications for what is expected to be a blockbuster seller.
